Literature DB >> 19029274

Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr(-/-) mice.

N a Braun1, N S Wade, E K Wakeland, A S Major.   

Abstract

Individuals suffering from systemic lupus erythematosus (SLE) are predisposed to accelerate cardiovascular disease. Our laboratory has recently developed an animal model of SLE-accelerated atherosclerosis. We have shown that, following 8 weeks feeding high fat Western diet, radiation chimeras consisting of SLE-derived haematopoietic cells transferred to low-density lipoprotein (LDL)r(-/-) mice (LDLr.Sle) have increased atherosclerosis compared with C57Bl/6 bone marrow recipients (LDLr.B6). However, this feeding regimen resulted in significant mortality in SLE-susceptible mice compared with controls with surviving animals having extremely elevated serum cholesterol (>500 mg/dL) and increased serum markers of kidney pathology. To test the hypothesis that SLE-associated autoimmune dysregulation can exacerbate atherosclerosis under more mild serum cholesterol conditions (approximately 200 mg/dL), we examined SLE and lesion development in radiation chimeras fed either a normal chow or high fat Western diet for 8 weeks. High fat fed LDLr.Sle mice exhibited increased mortality and were significantly more hypertensive. LDLr.Sle mice had greater titres of antibodies against dsDNA, oxLDL and phospholipid compared with controls. Lupus-susceptibility increased the atherosclerotic lesions and the percentage of CD4(+) T cells in the lesions of proximal aortas, independent of diet. These data show that increased dyslipidemia resulting from high-fat feeding can exacerbate autoimmunity and associated vascular complications. Conversely, they also show that autoimmune dysregulation can accelerate atherosclerosis in LDLr-deficient animals independent of feeding high fat diet. Collectively this study provides additional evidence that the accelerated atherosclerosis observed in SLE is autoimmune associated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19029274      PMCID: PMC2662384          DOI: 10.1177/0961203308093551

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  39 in total

Review 1.  Atherosclerosis. the road ahead.

Authors:  C K Glass; J L Witztum
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Atherosclerosis, autoimmunity, and systemic lupus erythematosus.

Authors:  P Thiagarajan
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

3.  Antibodies against oxidized LDL for non-invasive diagnosis of atherosclerotic vascular disease.

Authors:  B de Geest; D Collen
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

4.  Atherosclerosis and lupus: a work in progress.

Authors:  M D Lockshin; J E Salmon; M J Roman
Journal:  Arthritis Rheum       Date:  2001-10

5.  Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice.

Authors:  J George; D Harats; B Gilburd; A Afek; A Shaish; J Kopolovic; Y Shoenfeld
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

Review 6.  Autoantibodies against oxidized LDL. A potential marker for atherosclerosis.

Authors:  J T Wu; L L Wu
Journal:  Clin Lab Med       Date:  1997-09       Impact factor: 1.935

7.  Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome.

Authors:  M J Roman; J E Salmon; R Sobel; M D Lockshin; L Sammaritano; J E Schwartz; R B Devereux
Journal:  Am J Cardiol       Date:  2001-03-01       Impact factor: 2.778

8.  Auto-antibodies against oxidized LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia.

Authors:  J E Paiker; F J Raal; M von Arb
Journal:  Ann Clin Biochem       Date:  2000-03       Impact factor: 2.057

Review 9.  Antibodies against oxidized LDL--theory and clinical use.

Authors:  A Steinerová; J Racek; F Stozický; T Zima; L Fialová; A Lapin
Journal:  Physiol Res       Date:  2001       Impact factor: 1.881

10.  Risk factors for cardiovascular disease in systemic lupus erythematosus.

Authors:  E Svenungsson; K Jensen-Urstad; M Heimbürger; A Silveira; A Hamsten; U de Faire; J L Witztum; J Frostegård
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

View more
  18 in total

1.  Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia.

Authors:  Nicole A Braun; Yanice V Mendez-Fernandez; Roman Covarrubias; Steven A Porcelli; Paul B Savage; Hideo Yagita; Luc Van Kaer; Amy S Major
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-06-10       Impact factor: 8.311

Review 2.  Immunomodulation of vascular diseases: atherosclerosis and autoimmunity.

Authors:  G-P Shi
Journal:  Eur J Vasc Endovasc Surg       Date:  2010-02-25       Impact factor: 7.069

3.  T cells expressing the lupus susceptibility allele Pbx1d enhance autoimmunity and atherosclerosis in dyslipidemic mice.

Authors:  Wei Li; Ahmed S Elshikha; Caleb Cornaby; Xiangyu Teng; Georges Abboud; Josephine Brown; Xueyang Zou; Leilani Zeumer-Spataro; Brian Robusto; Seung-Chul Choi; Kristianna Fredenburg; Amy Major; Laurence Morel
Journal:  JCI Insight       Date:  2020-06-04

4.  Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.

Authors:  Ashley J Wilhelm; Amy S Major
Journal:  Int J Clin Rheumtol       Date:  2012-10-01

Review 5.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

Review 6.  Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus.

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Annu Rev Med       Date:  2012-09-27       Impact factor: 13.739

Review 7.  The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity.

Authors:  N S Wade; A S Major
Journal:  Thromb Haemost       Date:  2011-10-06       Impact factor: 5.249

8.  Autoimmune-mediated glucose intolerance in a mouse model of systemic lupus erythematosus.

Authors:  Curtis L Gabriel; Patricia B Smith; Yanice V Mendez-Fernandez; Ashley J Wilhelm; Audrey Musi Ye; Amy S Major
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-10-02       Impact factor: 4.310

9.  The lupus susceptibility locus Sle3 is not sufficient to accelerate atherosclerosis in lupus-susceptible low density lipoprotein receptor-deficient mice.

Authors:  N S Wade; B G Stevenson; D S Dunlap; A S Major
Journal:  Lupus       Date:  2009-10-22       Impact factor: 2.911

10.  17-β Estradiol reduces atherosclerosis without exacerbating lupus in ovariectomized systemic lupus erythematosus-susceptible LDLr(-/-) mice.

Authors:  K A Shelton; J M Cline; J A Cann
Journal:  Atherosclerosis       Date:  2013-01-18       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.